Elevated Level of IFN Type I in SLE Patients
Conditions
Brief summary
Elevated level of IFN type I in SLE patients associated with certain serum biomarkers (galectin -1,-3,-9; cytokine profile - 20 plex panel - GM-CSF, IFN-γ, IL-2, -4,-5,-6,-7,-8,-10,-13,-15,-17,-18, IP-10. MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α, TNF-RII, BAFF, APRIL), clinical and laboratory manifestations, activity and duration pf the disease and SLE patients quality of life. Standard immunosuppressive and anti-B-cell therapy can reduce the IFN type I and associated biomarkers levels in patients with high and moderate disease activity (SLEDAI-2К ≥6).
Interventions
OTHERstudy of IFNGS expression biomarkers
Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.
Sponsors
AstraZeneca
V.A. Nasonova Research Institute of Rheumatology, Moscow
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-60 years old 2. Patients with SLE (SLICC/ACR 2012) confirmed by rheumatologist 3. Provided written informed consent before any study-related procedures are performed. 4. Ability to attend scheduled visits 5. No positive changes in the course of standard of care SLE therapy (glucocorticoids in stable doses, hydroxychloroquine and/or immunosuppressant therapy) at least 30 days before screening.
Exclusion criteria
1. Participation in any other clinical study 2. Pregnancy or pregnancy planning in next 12 months, lactation 3. Acute infectious disease or relapse of chronic infectious disease. 4. Receiving any of biologic agent or Janus-kinases inhibitors during 24 months prior to screening. 5. Active severe or unstable neuropsychiatric SLE manifestations (convulsion, psychosis, delirium, hallucinations, coma, transverse myelitis).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathogenetic, clinical and prognostic significance of IFN stimulated genes expression - IFNGS biomarkers in SLE patients | Sept 1 2022 - Nov 1 2022 | Pathogenetic, clinical and prognostic significance of IFN stimulated genes expression - IFNGS biomarkers (IFI44L, MX1, IFIT 1, RSAD2, EPSTI1), serum biomarkers (galectin -1,-3,-9; cytokine profile - 20 plex panel - GM-CSF, IFN-γ, IL-2, -4,-5,-6,-7,-8,-10,-13,-15,-17,-18, IP-10. MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α), TNF-α receptors type II (TNF-RII), В-cell activation factors (BAFF, APRIL) in SLE patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of IFN stimulated genes | Nov 1 2022 - Oct 31 2024 | Rate of IFN stimulated genes hyper-expression, serum biomarkers level (galectin -1,-3,-9; cytokine profile - 20 plex panel - GM-CSF, IFN-γ, IL-2, -4,-5,-6,-7,-8,-10,-13,-15,-17,-18, IP-10. MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α), TNF-α receptors type II level (TNF-RII), В-cell activation factors level (BAFF, APRIL) in SLE patient's blood. |
| IFN stimulated genes hyper-expression and serum biomarkers level | Nov 1 2022 - Oct 31 2024 | IFN stimulated genes hyper-expression and serum biomarkers level (galectin -1,-3,-9; cytokine profile - 20 plex panel - GM-CSF, IFN-γ, IL-2, -4,-5,-6,-7,-8,-10,-13,-15,-17,-18, IP-10. MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α), TNF-α receptors type II level (TNF-RII), В-cell activation factors level (BAFF, APRIL) associated with SLE clinical and laboratory manifestations (such as muco-cutaneous, joints, renal, hematological, immunological et ctr.), disease activity (assessed with SLEDAI-2k) and duration, patients' quality of life. |
| IFNGS | Nov 1 2022 - Oct 31 2024 | IFNGS alone or as a part of complex poly-parametric indexes is a predictor of standard immunosuppressive and anti-B-cell therapy effectiveness in SLE and flares prevention. |
Contacts
Primary ContactTatiana Popkova, MD
Backup ContactTatiana Panafidina, MD
Outcome results
None listed